Medical Health & Life Science Research News

Veterinary/animal vaccines market worth 8.66 billion USD by 2022 scrutinized in new research

Medical Market Research

According to a new market research report "Veterinary/Animal Vaccines Market Type (Porcine, Poultry, Companion Animal, Aquaculture), Disease (Porcine Parvovirus, Swine Pneumonia, Avian Influenza, Rabies, Clostridial Diseases), Technology (Inactivated, Toxoid, Recombinant) - Global Forecast to 2022", published by MarketsandMarkets™, the global market is expected to reach USD 8.66 Billion by 2022 from USD 6.50 Billion in 2017, at a CAGR of 5.9% during the forecast period (2017-2022).

- Advertising -

Browse 148 Market Data Tables and 26 Figures spread through 161 Pages and in-depth TOC on "Veterinary/Animal Vaccines Market"…m_campaign=PaidPR

Early buyers will receive 10% customization on this report 

The major factors driving the growth of this market include growth in livestock population and repeated breakouts of livestock diseases; increasing adoption of companion animals; rising incidence of zoonotic diseases; initiatives by various government agencies, animal associations, and leading players; and the introduction of new types of vaccines.

The porcine vaccines segment is expected to hold the largest market share during the forecast period 

Based on the type, the Veterinary Vaccines Market is segmented into porcine vaccines, poultry vaccines, livestock vaccines, companion animal vaccines, aquaculture vaccines and other animal vaccines. In 2017, the porcine vaccines segment is expected to account for the largest share of the market.

The dominant share of this segment can be attributed to the increasing porcine population, growing awareness about animal vaccination, and outbreaks of porcine diseases such as PRRS (Porcine Reproductive & Respiratory Syndrome), swine influenza, and Auzeszkys Disease (AD).

- Advertising -

Download PDF Brochure:…m_campaign=PaidPR

The recombinant vaccines segment expected to grow at the highest rate in the next five years 

On the basis of technology, the market is classified into live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and other vaccines. The recombinant vaccines segment is the fastest-growing technology segment in the Veterinary Vaccines Market.

Recombinant vaccines offer multiple advantages such as the lack of need for adjuvants, the stability offered by the vaccine that allows it to remain viable at ambient temperatures, and these vaccines are free from pathogen contamination. Moreover, recombinant vaccines exhibit no post-vaccination reactions and higher safety, as there is no risk of contracting a disease from the agent.

Such advantages are making recombinant vaccines more popular among end users.

Access Report:…m_campaign=PaidPR

Europe expected to dominate the Veterinary Vaccines Market in 2017 

In 2017, Europe is expected to be the largest market for veterinary vaccines, followed by North America. However, the APAC region is expected to grow at the highest rate during the forecast period.

Rising pet adoption, expansion of key vaccine players in the APAC region, and the wide range of new product launches and investments in manufacturing facilities, especially in India, China, and Thailand are driving market growth in this region.

Zoetis (US), Merck Animal Health (US), Elanco (US), Boehringer Ingelheim (Germany), Ceva (France), Phibro Animal Health (US), and Virbac (France) are key players in the Veterinary Vaccines Market. Other notable players operating in this market include Vetoquinol (France), Hester (India), Hipra (Spain), IDT Biologika (Germany), China Animal Husbandry (China), Biogenesis Bago (Argentina), Tianjin Ringpu (China), and Jinyu Bio-technology (China).

News From

MarketsandMarkets™ - Business ResearchMarketsandMarkets™
Category: Market Research Publishers and RetailersCompany about: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth ...
This email address is being protected from spambots. You need JavaScript enabled to view it.